How today’s MS treatment decisions impact tomorrow? CP 2

With the collaboration of Prof. E. Gulowsen Celius (Oslo University, Norway), Prof. G. Laureys (Ghent University Hospital) and Prof. D. Dive (Liege University Hospital)

__FILL_ME_OUT__
Lesduur: 150min
Gepubliceerd:
Accreditatie tot:

Om deze les te volgen dient u een account te hebben en moet u zich aanmelden.

Geen account? Registreer u hier.

As our use of new MS drugs progresses, real-world evidence starts becoming available that usefully complements trials-derived knowledge. Beyond informing us on how to best move from one drug to another one, it can also refine our understanding of the longer-term consequences of the treatment choices we pose today and help us best tailoring drug choices to individual patient needs. To discuss these key elements, we have here a panel of experts who will complement mechanistic and trial considerations with their own extensive experiences, in order to share useable and practical advices and tips.